<DOC>
	<DOCNO>NCT02049203</DOCNO>
	<brief_summary>This study determine whether Ataciguat ( HMR1766 ) well-tolerated patient mild moderate calcific aortic valve stenosis . The primary focus study change blood pressure orthostatic tolerance ( i.e. , ability stand without pass ) , determine whether treatment Ataciguat result significant reduction blood pressure patient population .</brief_summary>
	<brief_title>Safety Ataciguat Patients With Moderate Calcific Aortic Valve Stenosis</brief_title>
	<detailed_description />
	<mesh_term>Constriction , Pathologic</mesh_term>
	<mesh_term>Aortic Valve Stenosis</mesh_term>
	<criteria>Age &gt; 50 year Male female sex Aortic valve area great 1.0 cm2 less 2.0 cm2 Aortic valve calcium level great 300 arbitrary unit chest CT Ejection fraction &gt; 50 % History orthostatic intolerance symptomatic hypotension Positive pregnancy test screen visit Nitrate use αantagonist medication use within 24 hour Systolic blood pressure &lt; 110 mm Hg Mean systemic arterial pressure &lt; 75 mm Hg Severe mitral aortic regurgitation Retinal optic nerve problem Recent ( ≤30 day ) acute coronary syndrome Oxygen saturation &lt; 90 % room air Congenital valve disease Hepatic dysfunction/elevated liver enzymes Prescription drug know alter nitric oxidesoluble guanylate cyclasecyclic guanosine monophosphate signaling ( sildenafil , nitrate , etc . ) History orthostatic intolerance Concomitant participation trial Mayo Clinic elsewhere .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>